St. Jude Gains Force-Sensing Catheter Technology With Endosense Acquisition
This article was originally published in The Gray Sheet
Executive Summary
The $170 million acquisition, plus milestones, gives St. Jude Medical access to contact-force-sensing catheter ablation technology, strengthening its cardiac ablation pipeline and offering opportunities to enhance currently marketed products.
You may also be interested in...
AF Ablation Procedures Driving CRM Market Expansion
Cardiac rhythm management device sales in the US are projected to grow at a compound annual rate of 2.9%, increasing to an estimated $8.2 billion in the year 2019. Two of the fastest growing sectors of the market, electrophysiology and ablation devices, will be driven by a 10% to 20% growth in the number of patients treated for atrial fibrillation.
Use The Force: St. Jude Hopes To Build AFib Footprint With Pressure-Sensing Catheter
The TactiCath Quartz irrigated ablation catheter, acquired in the Endosense deal in 2013, lets electrophysiologists monitor the force exerted by the catheter tip on the endocardium during an atrial fibrillation ablation procedure.
SJM’s Endosense Deal Highlights Growing Importance Of Contact Force Technology In AF Ablation
St. Jude Medical has acquired Swiss company Endosense, a pioneer in the field of contact force sensing for atrial fibrillation ablation. The $170 million plus milestones deal will enable St. Jude to compete more effectively against market leader Biosense Webster/J&J, but it also emphasizes the growing importance of contact force technology in the AF ablation space.